The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis

Jie Zhang; Xinyi Wang; Wende Tian; Tongxin Wang; Jundi Jia; Runmin Lai; Tong Wang; Zihao Zhang; Luxia Song; Jianqing Ju; Hao Xu

doi:10.3389/fcvm.2022.936817

The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis

Front Cardiovasc Med. 2022 Jul 27:9:936817. doi: 10.3389/fcvm.2022.936817. eCollection 2022.

Authors

Jie Zhang^{1

2}, Xinyi Wang^{1

3}, Wende Tian^{1

3}, Tongxin Wang^{1

2}, Jundi Jia^{1

2}, Runmin Lai^{1

3}, Tong Wang^{1

2}, Zihao Zhang^{1

2}, Luxia Song^{1

2}, Jianqing Ju¹, Hao Xu¹

Affiliations

¹ National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
² Graduate School, Beijing University of Chinese Medicine, Beijing, China.
³ Graduate School, China Academy of Chinese Medical Sciences, Beijing, China.

Abstract

Objective: The objective of this study was to measure the efficacy of various types and dosages of statins on C-reactive protein (CRP) levels in patients with dyslipidemia or coronary heart disease.

Methods: Randomized controlled trials were searched from PubMed, Embase, Cochrane Library, OpenGray, and ClinicalTrials.gov. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for data extraction and synthesis. The pairwise meta-analysis compared statins and controls using a random-effects model, and a network meta-analysis compared the types and dosages of statins using the Bayesian random-effects model. The PROSPERO registration number is CRD42021242067.

Results: The study included 37 randomized controlled trials with 17,410 participants and 20 interventions. According to the pairwise meta-analysis, statins significantly decreased CRP levels compared to controls (weighted mean difference [WMD] = -0.97, 95% confidence interval [CI] [-1.31, -0.64], P < 0.0001). In the network meta-analysis, simvastatin 40 mg/day appeared to be the best strategy for lowering CRP (Rank P = 0.18, WMD = -4.07, 95% CI = [-6.52, -1.77]). The same was true for the high-sensitivity CRP, non-acute coronary syndrome (ACS), <12 months duration, and clear measurement subgroups. In the CRP subgroup (rank P = 0.79, WMD = -1.23, 95% CI = [-2.48, -0.08]) and ≥12-month duration subgroup (Rank P = 0.40, WMD = -2.13, 95% CI = [-4.24, -0.13]), atorvastatin 80 mg/day was most likely to be the best. There were no significant differences in the dyslipidemia and ACS subgroups (P > 0.05). Node-splitting analysis showed no significant inconsistency (P > 0.05), except for the coronary heart disease subgroup.

Conclusion: Statins reduced serum CRP levels in patients with dyslipidemia or coronary heart disease. Simvastatin 40 mg/day might be the most effective therapy, and atorvastatin 80 mg/day showed the best long-term effect. This study provides a reference for choosing statin therapy based on LDL-C and CRP levels.

Keywords: C-reactive protein; coronary heart disease; dyslipidemia; network meta-analysis; statin.

Publication types

Systematic Review